Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,924
  • Shares Outstanding, K 10,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,960 K
  • EBIT $ -21 M
  • EBITDA $ -21 M
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 129.46% ( -86.28%)
  • Historical Volatility 101.20%
  • IV Percentile 63%
  • IV Rank 48.73%
  • IV High 253.42% on 08/06/24
  • IV Low 11.66% on 07/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 125
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 421
  • Open Int (30-Day) 255

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.79 +48.75%
on 11/21/24
4.88 -14.96%
on 12/09/24
+0.31 (+8.07%)
since 11/08/24
3-Month
2.79 +48.75%
on 11/21/24
4.88 -14.96%
on 12/09/24
+0.65 (+18.57%)
since 09/09/24
52-Week
2.79 +48.75%
on 11/21/24
11.99 -65.39%
on 03/25/24
+0.31 (+8.07%)
since 12/08/23

Most Recent Stories

More News
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 0.8800 (-0.34%)
CADL : 5.05 (-1.75%)
AZN : 68.58 (+0.56%)
MRUS : 43.74 (-2.04%)
LTRN : 4.15 (+4.27%)
ONC.TO : 1.25 (-0.79%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 0.8800 (-0.34%)
ONC.TO : 1.25 (-0.79%)
CADL : 5.05 (-1.75%)
AZN : 68.58 (+0.56%)
MRUS : 43.74 (-2.04%)
LTRN : 4.15 (+4.27%)
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END

TREIF : 0.4072 (-5.50%)
TRUE.CN : 0.5600 (unch)
NVDA : 138.81 (-2.55%)
HWAIF : 1.3150 (-1.13%)
AIDX.TO : 1.85 (-1.07%)
LTRN : 4.15 (+4.27%)
MDT : 83.96 (-0.06%)
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END

VERS.NE : 0.4400 (-15.38%)
TREIF : 0.4072 (-5.50%)
TRUE.CN : 0.5600 (unch)
HWAIF : 1.3150 (-1.13%)
AIDX.TO : 1.85 (-1.07%)
VRSSF : 0.3151 (-12.47%)
VERS : 49.42 (+0.55%)
PATH : 15.50 (+4.66%)
LTRN : 4.15 (+4.27%)
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

TREIF : 0.4072 (-5.50%)
TRUE.CN : 0.5600 (unch)
HWAIF : 1.3150 (-1.13%)
AIDX.TO : 1.85 (-1.07%)
VRSSF : 0.3151 (-12.47%)
VERS : 49.42 (+0.55%)
PATH : 15.50 (+4.66%)
LTRN : 4.15 (+4.27%)
8 Best Artificial Intelligence Stocks Under $10

If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more.

C : 71.86 (-0.40%)
GME : 27.93 (-3.89%)
INTC : 20.81 (-0.53%)
LRCX : 77.45 (+1.12%)
LTRN : 4.15 (+4.27%)
MSFT : 446.02 (+0.55%)
MOVE : 6.05 (+1.17%)
NVDA : 138.81 (-2.55%)
TSLA : 389.79 (+0.15%)
AMD : 130.87 (-5.57%)
NIO : 5.18 (+12.36%)
NOTE : 0.8350 (-6.18%)
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace,...

LTRN : 4.15 (+4.27%)
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 4.15 (+4.27%)
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 4.15 (+4.27%)
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 4.15 (+4.27%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 5.43
2nd Resistance Point 5.16
1st Resistance Point 4.65
Last Price 4.15
1st Support Level 3.87
2nd Support Level 3.60
3rd Support Level 3.09

See More

52-Week High 11.99
Fibonacci 61.8% 8.48
Fibonacci 50% 7.39
Fibonacci 38.2% 6.30
Last Price 4.15
52-Week Low 2.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar